GSK Tykerb Positive Trial Data Prompt Earlier Submission
Data monitoring committee halts Phase III trial of lapatinib in breast cancer after it exceeds its primary endpoint.
Data monitoring committee halts Phase III trial of lapatinib in breast cancer after it exceeds its primary endpoint.